礼来再下一城!Bimagrumab注射液中国提交IND申请,减重不减肌未来不是梦?

药渡
07 Apr

来源:药渡撰文:Pharmadeep编辑:活力哈哈2025年4月3日,中国国家药监局药品审评中心(CDE)官网公示,礼来公司提交Bimagrumab注射液临床试验申请(IND)。尽管具体适应症尚未披露,但结合礼来全球研发管线及靶点机制,Bimagrumab极可能瞄准肌肉萎缩或代谢性疾病领域。本文将从靶点机制、国内外研发进展及市场竞争格局三大维度,剖析该药物的潜在价值与行业影响。图片来源:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10